Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Drug Evaluation × Breast × Clear all

Phase

Phase 2 2 Phase 3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 3 Lymphoid 2 Other solid neoplasm 1 Gynecologic 1 Breast 1

Conditions

Postmenopausal Women With ER+ HER2- Primary Breast Cancer 1

Interventions

Paclitaxel 88 Trastuzumab 73 pembrolizumab 69 Cyclophosphamide 60 Fulvestrant 58 Capecitabine 43 Docetaxel 40 Carboplatin 40 Lapatinib 39 palbociclib 35 Letrozole 33 Doxorubicin 26 olaparib 25 Taxes 24 Gemcitabine 24 Nivolumab 23 Magnetic Resonance Spectroscopy 23 130-nm albumin-bound paclitaxel 22 Everolimus 21 Biopsy 21 Cisplatin 19 abemaciclib 18 Specimen Handling 18 Bevacizumab 18 Albumin-Bound Paclitaxel 18 ribociclib 17 Radiotherapy 17 Ado-Trastuzumab Emtansine 17 pertuzumab 16 exemestane 16

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03236974 2020-02-06

D6090C00002

AstraZeneca

Phase 1 Completed

Postmenopausal Women With ER+ HER2- Primary Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡